Please assess the completion status of the following clinical trial:

Trial Title: Role of Anti-IgE in Severe Childhood Eczema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Children between the ages of 4-19 years~2. Severe eczema~3. Raised SpIgE or SPT to at least 1 food allergen or 1 aeroallergen AND/OR~4. Clinical impression that allergic exposures cause worsening eczema.~5. Total IgE level \>300 kU/l~6. Clinically proven IgE-mediated allergic disease.~7. Written informed consent to participate.~Exclusion criteria:~1. Inability to comply with 2-4 weekly injections and clinic visits~2. Evidence of underlying immune compromise, autoimmune disease, immune complex mediated conditions.~3. Uncontrolled infection or unstable eczema.~4. Malignancy or a history of malignancy.~5. Pre-existing hepatic or renal impairment~6. Known cardiovascular or ischaemic cerebrovascular abnormality.~7. Other serious or uncontrolled systemic disease.~8. Pregnancy or lactation.~9. Known history of hypersensitivity or anaphylaxis to anti-IgE injections or its constituents.~10. Insufficient understanding of the trial assessments.~11. Participation in a CTIMP in the previous 60 days or (if known) 4 half-lives of the relevant medication, whichever is the greater.~12. Investigator feels that there is a good clinical reason why the child would be unsuitable.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- Xolair/Omalizumab (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).